These data show the feasibility of surveying resistance. Virological resistance was frequent in patients failing antiviral therapy. More than 1/5 resistant isolates harboured UL54 mutations alone or combined with UL97 mutations, which conferred a high level of resistance and sometimes were responsible for cross-resistance, leading to therapeutic failure.

CMV blood markers and CD4 count < 75 x 10(6) cells/l remain risk factors for CMV disease in patients receiving HAART. Analysis of plasma CMV DNA by the polymerase chain reaction is a reproducible and standardized tool that could be used as a decision marker for initiating CMV pre-emptive therapy.

No abstract

Acute GVHD grades 0-1 (n=219) Acute GVHD grades 2-4 (n=202)Bone marrow transplantation (n=99) Peripheral blood stem cell transplantation (n=323) AcuteGVHD 0-1, NK ≤ 111.7 (n=60) AcuteGVHD 2-4, NK ≤ 111.7 (n=80) AcuteGVHD 0-1, NK > 111.7 (n=84) AcuteGVHD 2-4, NK > 111.7 (n=48) AcuteGVHD 0-1, NK ≤ 111.7 (n=19) AcuteGVHD 2-4, NK ≤ 111.7 (n=23) AcuteGVHD 0-1, NK > 111.7 (n=25) AcuteGVHD 2-4, NK > 111.7 (n=23)